AlphAIalphai — Financial news for AI agents
londoninsider.co.ukAUG 202 min read$AUPH

Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036

Aurinia Pharmaceuticals (AUPH) settled a patent dispute with Teva (TEVA), delaying a generic version of Lupkynis until 2036. The deal boosted AUPH shares by 7%. Aurinia also settled with Sun Pharma in 2023 and faces ongoing litigation with other generics makers. Lupkynis is Aurinia's sole marketed drug, with H1 2026 revenue up 21% YoY to $161M, and full-year guidance of $315M-$325M.

Original reporting
londoninsider.co.uk
Published Aug 20, 2026, 4:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 20, 2026, 4:47 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About alphai AI DeskScoring methodologyReport an issue
Aurinia Pharmaceuticals (AUPH) Secures Patent Settlement With Teva, Blocking Lupkynis Generic Until 2036 — source image
Source · londoninsider.co.uk
Decision brief

The 30-second read

$AUPHBullishMed
01

Why it matters

The settlement removes immediate generic competition, supporting revenue forecasts and share price.

02

Market read

The news provides a clear catalyst for AUPH's stock, offering a short-term trading opportunity.

03

What to watch

Ongoing litigation with other generics could still erode market share despite the settlement.

Relevance 7/10Novelty 7/10Timing: today

Background

Aurinia's Lupkynis is its sole marketed product; patent protection is critical for revenue.

Company-level read

Ticker impact

$AUPHBullishHigh confidence
Context

Aurinia announced a patent settlement with Teva blocking a generic Lupkynis until 2036, causing a 7% share price rise.

Expected impact

Potential further upside if market digests the extended exclusivity timeline.

Evidence & confidence

Extended patent protection is material for a single-product biotech; investors already reacted positively.

Market effects

Sector

Strengthens Lupus treatment niche, may pressure peers like GSK, Roche, AstraZeneca.

Regional

U.S. biotech sector sees a boost from exclusivity news.

Global

Limited to biotech investors; no broad market effect.

Counterpoint

What could challenge this read

If Teva challenges the settlement or wins an appeal, the exclusivity could be shortened.

Key entities

  • company
    Aurinia Pharmaceuticals

    Biotech firm developing Lupkynis for lupus.

  • company
    Teva Pharmaceuticals

    Generic drug manufacturer involved in the settlement.

Read at source← All news

Also covered by

1 outlet

Related articles

AUG 20
$AUPHMed

Aurinia Settles Voclosporin Patent Litigation With Teva, Stock Rises

Aurinia Pharmaceuticals settled patent litigation with Teva, pushing back potential generic competition for voclosporin until 2036. Aurinia's stock rose 6% on the news. Lupkynis, Aurinia's voclosporin product, recorded $153M in sales in H1 2026, up 21% YoY. Aurinia's patent litigation with other companies continues.

zacks.com2 min
AUG 19
$AUPHMed

Aurinia Settles Patent Litigation with Teva

Aurinia Pharmaceuticals (AUPH) settled patent litigation with Teva, which agreed to not launch its generic voclosporin product until December 7, 2036, unless certain conditions are met. Teva acknowledged the validity of Aurinia's patents, which expire in December 2037. Aurinia's litigation against other companies continues.

leaderpost.com2 min
AUG 19
$AUPHMed

Aurinia stock falls on Teva patent settlement for voclosporin

Aurinia Pharmaceuticals (AUPH) shares fell 2% after announcing a patent settlement with Teva (TEVA) for generic voclosporin, allowing Teva to launch its version no earlier than 2036. The agreement validates Aurinia's patents and resolves litigation. Voclosporin is marketed as LUPKYNIS for lupus nephritis. Aurinia continues patent actions against other companies.

investing.com4 min
AUG 6
$AUPHMed

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aurinia Pharmaceuticals (NASDAQ: AUPH) reported Q2 and first-half 2026 results. Total revenue rose to $83.2M and $160.9M, and net product sales of LUPKYNIS increased to $79.4M and $153.0M. Net income was $37.4M and $71.8M. Cash and investments were $443.1M at June 30, 2026. 2026 guidance: revenue $315M-$325M, net product sales $305M-$315M. It also initiated the PRESERVE Phase 4 study of LUPKYNIS plus biologics.

thestarphoenix.com5 min